TCR diversity - a universal cancer immunotherapy biomarker?

J Immunother Cancer. 2016 Nov 15;4:69. doi: 10.1186/s40425-016-0175-4. eCollection 2016.

Abstract

Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.

Keywords: Prostate cancer; Sipuleucel-T; T-cell diversity; TCR sequencing; Tumor vaccine.

Publication types

  • Editorial
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Animals
  • Biomarkers
  • Genetic Variation*
  • Humans
  • Immunotherapy
  • Neoplasms / genetics*
  • Neoplasms / immunology*
  • Neoplasms / metabolism
  • Neoplasms / therapy
  • Receptors, Antigen, T-Cell / genetics*
  • Receptors, Antigen, T-Cell / metabolism
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / metabolism*

Substances

  • Biomarkers
  • Receptors, Antigen, T-Cell